These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 24115324)
1. Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3. Neubauer S; Rechenmacher F; Beer AJ; Curnis F; Pohle K; D'Alessandria C; Wester HJ; Reuning U; Corti A; Schwaiger M; Kessler H Angew Chem Int Ed Engl; 2013 Oct; 52(44):11656-9. PubMed ID: 24115324 [TBL] [Abstract][Full Text] [Related]
2. Functionalizing αvβ3- or α5β1-selective integrin antagonists for surface coating: a method to discriminate integrin subtypes in vitro. Rechenmacher F; Neubauer S; Polleux J; Mas-Moruno C; De Simone M; Cavalcanti-Adam EA; Spatz JP; Fässler R; Kessler H Angew Chem Int Ed Engl; 2013 Jan; 52(5):1572-5. PubMed ID: 23345131 [No Abstract] [Full Text] [Related]
3. Complementary, Selective PET Imaging of Integrin Subtypes α5β1 and αvβ3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin. Notni J; Steiger K; Hoffmann F; Reich D; Kapp TG; Rechenmacher F; Neubauer S; Kessler H; Wester HJ J Nucl Med; 2016 Mar; 57(3):460-6. PubMed ID: 26635338 [TBL] [Abstract][Full Text] [Related]
4. Single cell tracking assay reveals an opposite effect of selective small non-peptidic α5β1 or αvβ3/β5 integrin antagonists in U87MG glioma cells. Ray AM; Schaffner F; Janouskova H; Noulet F; Rognan D; Lelong-Rebel I; Choulier L; Blandin AF; Lehmann M; Martin S; Kapp T; Neubauer S; Rechenmacher F; Kessler H; Dontenwill M Biochim Biophys Acta; 2014 Sep; 1840(9):2978-87. PubMed ID: 24810979 [TBL] [Abstract][Full Text] [Related]
5. In vivo biokinetic and metabolic characterization of the ⁶⁸Ga-labelled α5β1-selective peptidomimetic FR366. D'Alessandria C; Pohle K; Rechenmacher F; Neubauer S; Notni J; Wester HJ; Schwaiger M; Kessler H; Beer AJ Eur J Nucl Med Mol Imaging; 2016 May; 43(5):953-963. PubMed ID: 26497698 [TBL] [Abstract][Full Text] [Related]
6. Pharmacophoric modifications lead to superpotent αvβ3 integrin ligands with suppressed α5β1 activity. Neubauer S; Rechenmacher F; Brimioulle R; Di Leva FS; Bochen A; Sobahi TR; Schottelius M; Novellino E; Mas-Moruno C; Marinelli L; Kessler H J Med Chem; 2014 Apr; 57(8):3410-7. PubMed ID: 24654918 [TBL] [Abstract][Full Text] [Related]
7. A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen. Meerovitch K; Bergeron F; Leblond L; Grouix B; Poirier C; Bubenik M; Chan L; Gourdeau H; Bowlin T; Attardo G Vascul Pharmacol; 2003 Feb; 40(2):77-89. PubMed ID: 12646396 [TBL] [Abstract][Full Text] [Related]
8. Targeting integrins αvβ3 and α5β1 with new β-lactam derivatives. Galletti P; Soldati R; Pori M; Durso M; Tolomelli A; Gentilucci L; Dattoli SD; Baiula M; Spampinato S; Giacomini D Eur J Med Chem; 2014 Aug; 83():284-93. PubMed ID: 24973662 [TBL] [Abstract][Full Text] [Related]
9. Role of α5β1 and αvβ3 integrins in relation to adhesion and spreading dynamics of prostate cancer cells interacting with fibronectin under in vitro conditions. Stachurska A; Elbanowski J; Kowalczyńska HM Cell Biol Int; 2012 Oct; 36(10):883-92. PubMed ID: 22686483 [TBL] [Abstract][Full Text] [Related]
10. Variation of Specific Activities of 68Ga-Aquibeprin and 68Ga-Avebetrin Enables Selective PET Imaging of Different Expression Levels of Integrins α5β1 and αvβ3. Notni J; Steiger K; Hoffmann F; Reich D; Schwaiger M; Kessler H; Wester HJ J Nucl Med; 2016 Oct; 57(10):1618-1624. PubMed ID: 27151985 [TBL] [Abstract][Full Text] [Related]
11. A molecular toolkit for the functionalization of titanium-based biomaterials that selectively control integrin-mediated cell adhesion. Rechenmacher F; Neubauer S; Mas-Moruno C; Dorfner PM; Polleux J; Guasch J; Conings B; Boyen HG; Bochen A; Sobahi TR; Burgkart R; Spatz JP; Fässler R; Kessler H Chemistry; 2013 Jul; 19(28):9218-23. PubMed ID: 23744802 [TBL] [Abstract][Full Text] [Related]
12. Single and combined effects of alphavbeta3- and alpha5beta1-integrins on capillary tube formation in a human fibrinous matrix. Laurens N; Engelse MA; Jungerius C; Löwik CW; van Hinsbergh VW; Koolwijk P Angiogenesis; 2009; 12(3):275-85. PubMed ID: 19449108 [TBL] [Abstract][Full Text] [Related]
13. Development of isoxazoline-containing peptidomimetics as dual αvβ3 and α5β1 integrin ligands. Tolomelli A; Gentilucci L; Mosconi E; Viola A; Dattoli SD; Baiula M; Spampinato S; Belvisi L; Civera M ChemMedChem; 2011 Dec; 6(12):2264-72. PubMed ID: 21953988 [TBL] [Abstract][Full Text] [Related]
14. Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and alphavbeta3 in atherosclerosis. Al-Fakhri N; Wilhelm J; Hahn M; Heidt M; Hehrlein FW; Endisch AM; Hupp T; Cherian SM; Bobryshev YV; Lord RS; Katz N J Cell Biochem; 2003 Jul; 89(4):808-23. PubMed ID: 12858346 [TBL] [Abstract][Full Text] [Related]
15. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Beer AJ; Grosu AL; Carlsen J; Kolk A; Sarbia M; Stangier I; Watzlowik P; Wester HJ; Haubner R; Schwaiger M Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6610-6. PubMed ID: 18006761 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme. Merlino F; Daniele S; La Pietra V; Di Maro S; Di Leva FS; Brancaccio D; Tomassi S; Giuntini S; Cerofolini L; Fragai M; Luchinat C; Reichart F; Cavallini C; Costa B; Piccarducci R; Taliani S; Da Settimo F; Martini C; Kessler H; Novellino E; Marinelli L J Med Chem; 2018 Jun; 61(11):4791-4809. PubMed ID: 29775303 [TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of a new class of selective integrin alpha5beta1 antagonists. Stragies R; Osterkamp F; Zischinsky G; Vossmeyer D; Kalkhof H; Reimer U; Zahn G J Med Chem; 2007 Aug; 50(16):3786-94. PubMed ID: 17616113 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds. Benfatti F; Cardillo G; Fabbroni S; Galzerano P; Gentilucci L; Juris R; Tolomelli A; Baiula M; Spartà A; Spampinato S Bioorg Med Chem; 2007 Dec; 15(23):7380-90. PubMed ID: 17869121 [TBL] [Abstract][Full Text] [Related]
19. Hydrogel micropillars with integrin selective peptidomimetic functionalized nanopatterned tops: a new tool for the measurement of cell traction forces transmitted through αvβ3- or α5β1-integrins. Rahmouni S; Lindner A; Rechenmacher F; Neubauer S; Sobahi TR; Kessler H; Cavalcanti-Adam EA; Spatz JP Adv Mater; 2013 Nov; 25(41):5869-74. PubMed ID: 23913640 [TBL] [Abstract][Full Text] [Related]
20. αvβ3- or α5β1-Integrin-Selective Peptidomimetics for Surface Coating. Mas-Moruno C; Fraioli R; Rechenmacher F; Neubauer S; Kapp TG; Kessler H Angew Chem Int Ed Engl; 2016 Jun; 55(25):7048-67. PubMed ID: 27258759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]